Metabolic dysfunction-associated steatotic liver disease (MASLD) affects around one in three adults and is closely linked to obesity, type 2 diabetes and cardiovascular disease. This session will discuss the burden of MASLD in clinical practice, the relationship between liver and cardiometabolic health, and practical approaches to identifying patients at risk of advanced fibrosis using simple non-invasive tests. The presentation will also consider emerging management strategies and the importance of multidisciplinary care.